Pfizer overhaul faces timing dilemma

Article Abstract:

New Chief Executive Officer Jeffrey B. Kindler, Pfizer Inc. of the United States is to institute a restructuring plan. The world's largest pharmaceutical house needs a turnaround for flat sales and dsappointing drug line research results. Sales for the fourth quarter were $12.6 billion.

Organizational history, Pfizer Inc., Company restructuring/company reorganization, Reorganization and restructuring, PFE, Company organization, Financial report

---

J&J profit rises on drug strength, Medicare switch

Article Abstract:

Johnson & Johnson of the United States posted an increase in third quarter profit by 8.7 percent to $2.76 billion. The pharmaceutical company was buoyed by an improved pharmaceutical market, less competition from generic rivals and beneficial results from the Medicare drug insurance.

Sales, profits & dividends, Company sales and earnings, Company earnings/profit, Johnson & Johnson, JNJ

---

Similar abstracts:

• Abstracts: How Bristol-Myers fumbled defense of $4 billion drug. Pfizer's strategy takes shape; Europe sales team may be cut deeply; reorganizing R&D
• Abstracts: Profits at European plane makers soar. BAe profit matched expectations in half. Airbus, in a risky bet, to raise production of A320
• Abstracts: An integrated production and inventory model to dampen upstream demand variability in the supply chain. Genetic algorithms for supply-chain scheduling: a case study in the distribution of ready-mixed concrete
• Abstracts: Detailed layout planning for irregularly-shaped machines with transportation path design. Analyzing the effect of the inventory policy on order and inventory variability with linear control theory
• Abstracts: Pirelli Chairman considers reducing Telecom Italia stake. Telecom Italia to unveil plan to modernize

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.